Paul Bisaro
Paul Bisaro's purchase track record
Paul Bisaro has no open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/14/2026 | MYGN | $28K | -12.4% | pending | — |
| 5/13/2026 | ZTS | $152K | -0.4% | pending | — |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Goldman Sachs initiates Zoetis coverage with Neutral rating. Goldman Sachs began covering Zoetis with a Neutral rating and a $74 price target. This follows recent guidance cuts that the market initially shrugged off, alongside a new board appointment. The stock currently trades near a key support level, with an RSI of 71.0 indicating strong recent momentum.
Transaction History
| MYGN | ▲ Buy | Grant | 59,701 | $0 | 6/4/2026 | View on chart |
| MYGN | ▲ Buy | Open Market | 7,500 | $28K | 5/14/2026 | View on chart |
| ZTS | ▲ Buy | Open Market | 2,000 | $152K | 5/13/2026 | View on chart |
| ZTS | ▲ Buy | Option Exercise | 1,619 | — | 2/19/2026 | View on chart |
| MYGN | ▲ Buy | Grant | 49,796 | $0 | 6/5/2025 | View on chart |
| ZTS | ▲ Buy | Option Exercise | 1,225 | — | 2/8/2025 | View on chart |
| ZTS | ▲ Buy | Option Exercise | 1,236 | — | 2/6/2025 | View on chart |
| MYGN | ▲ Buy | Grant | 15,695 | $0 | 6/6/2024 | View on chart |
| ZTS | ▲ Buy | Option Exercise | 1,463 | — | 2/10/2024 | View on chart |
| ZTS | ▲ Buy | Option Exercise | 1,493 | — | 2/8/2024 | View on chart |
| MYGN | ▲ Buy | Grant | 7,575 | $0 | 6/1/2023 | View on chart |
| ZTS | ▲ Buy | Option Exercise | 1,626 | — | 2/11/2023 | View on chart |
| MYGN | ▲ Buy | Grant | 16,875 | $0 | 10/31/2022 | View on chart |
| TXMD | ▲ Buy | Option Exercise | 1,984 | — | 8/18/2022 | View on chart |
| ZTS | ▲ Buy | Option Exercise | 2,673 | — | 2/12/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Myriad Genetics Faces Risk Concerns Highlighted in Recent Analysis
An analysis on Yahoo points out three major risks for Myriad Genetics, raising questions about the company's future prospects. The stock is trading near its 14‑touch support level of $4.55 and sits above the 52‑week low of $2.74. Analysts average a target of $3.37, with a range from $2.00 to $5.00, suggesting a cautious view. The broader diagnostics market is also seeing growth, which may influence Myriad’s competitive environment.
Myriad Genetics Faces Risk Concerns Highlighted in Recent Analysis. An analysis on Yahoo points out three major risks for Myriad Genetics, raising questions about the company's future prospects. The stock is trading near its 14‑touch support level of $4.55 and sits above the 52‑week low of $2.74. Analysts average a target of $3.37, with a range from $2.00 to $5.00, suggesting a cautious view. The broader diagnostics market is also seeing growth, which may influence Myriad’s competitive environment.